To include your compound in the COVID-19 Resource Center, submit it here.

RSD1235: Phase II

In a North American double-blind Phase II trial in 60 patients, the high dose (2 mg) of RSD1235 met the primary endpoint of

Read the full 236 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE